PR Newswire Clinical TrialsOriginal article
AbelZeta Receives FDA IND Clearance for Phase 1b/2 Clinical Trial of C-CAR168 in Progressive Multiple Sclerosis
Phase 1approvedC-CAR168Positive
AI Analysis
Summary
AbelZeta Pharma received FDA IND clearance to initiate a Phase 1b/2 clinical trial of C-CAR168 in progressive multiple sclerosis. The approval expands the therapeutic development of C-CAR168 into chronic autoimmune disease indications with significant unmet medical needs.
Clinical Trial Data
Phase
1b/2
Outcome Details
FDA IND clearance received
Importance:6/10
Sentiment:
0.80
FDA approvalIND clearancePhase 1b/2Multiple SclerosisAutoimmune diseaseCell therapy
Read the original article
Published by PR Newswire Clinical Trials on September 14, 2026 11:30 AM